Locust Walk Insights

LOCUST WALK INSIGHTS

2023 Q3 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Third Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.

2023 Q2 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.

Deal Makers of Japan, Volume 3

The Deal Makers of Japan series aims to bridge the gap and offer insight to a global biopharma audience to the Japanese pharma industry. We are pleased to present the third volume of the Deal Makers of Japan - Exclusive Interviews with Japan’s best dealmakers,...

2023 Q1 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Frist Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.

RNA Therapeutics Landscape Overview

Locust Walk views RNA therapeutics in 5 key pillars: RNA Translation Inhibition, Protein Expression, RNA-Targeting Small Molecules, RNA Editing, and RNA-Mediated Protein and Transcriptome Regulation.

2022 Q3 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Third Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.

2022 Q2 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.

2022 Q1 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 First Quarter Report applies the latest data to analyze current activities in the life sciences deal...

2021 Year End Report

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Report applies the latest data to analyze current activities in the life sciences deal landscape.

Bought Not Sold

How do you start an M&A discussion? Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand: the majority of acquirers only became...

2021 Q3 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q3 Report: Global Trends in Biopharma Transactions applies the latest data to analyze...